Milrinone Decreases Blood Pressure
Milrinone causes peripheral vasodilation and typically decreases blood pressure, which is why it should be used with caution in hypotensive patients. This vasodilatory effect is a fundamental property of the drug that distinguishes it from pure inotropes like dobutamine.
Mechanism and Hemodynamic Effects
Milrinone is a phosphodiesterase-3 inhibitor that functions as an "inodilator"—it increases cardiac contractility while simultaneously causing vasodilation 1. The drug produces:
- Decreased systemic vascular resistance through arterial vasodilation 2
- Reduced mean arterial pressure (78 to 75 mm Hg in one study) 3
- Decreased pulmonary capillary wedge pressure and filling pressures 4, 3
- Increased cardiac output through both improved contractility and reduced afterload 5, 4
The vasodilatory properties are so prominent that milrinone decreased mean arterial pressure from 83 to 66 mmHg in surgical patients, requiring the addition of dopamine to restore blood pressure 6.
Clinical Implications and Precautions
Milrinone might cause peripheral dilation and should be used with caution in hypotensive patients 2. The guidelines are explicit about this risk:
- Avoid in patients with systolic blood pressure <90 mmHg 7
- Monitor blood pressure closely during infusion and slow or stop the rate if excessive decreases occur 1
- May require fluid administration secondary to vasodilatory effects 8
- In the OPTIME-CHF trial, symptomatic hypotension requiring intervention occurred more frequently with milrinone 7
Comparison with Other Inotropes
Unlike dobutamine, which can increase or maintain blood pressure through beta-adrenergic stimulation, milrinone consistently reduces systemic vascular resistance 4. In direct comparison studies:
- Milrinone significantly reduced mean systemic arterial pressure while dobutamine did not 4
- Dobutamine increased mean arterial pressure (90 to 117 mmHg) at higher doses, while milrinone decreased it 3
- The combination of milrinone plus dopamine was needed to maintain arterial pressure that milrinone alone could not sustain 6
When Hypotension Becomes Problematic
The blood pressure-lowering effect can be beneficial in patients with elevated systemic vascular resistance and adequate baseline blood pressure, as it reduces cardiac afterload. However, if prior vigorous diuretic therapy has caused significant decreases in cardiac filling pressure, milrinone should be cautiously administered with monitoring of blood pressure, heart rate, and clinical symptomatology 1.
The vasodilatory effect is dose-dependent and immediate—maximal reduction in systemic vascular resistance occurs within 5-10 minutes of bolus administration 5. This rapid onset means blood pressure changes must be anticipated and monitored closely from the start of infusion.